Skip to content

Molecular Mechanisms Underpinning Sarcopenic Obesity

Molecular Mechanisms Underpinning Sarcopenic Obesity

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06120647
Enrollment
60
Registered
2023-11-07
Start date
2020-01-28
Completion date
2025-12-30
Last updated
2023-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aging, Obesity, Sarcopenia, Sarcopenic Obesity

Brief summary

The coexistence of obesity and sarcopenia results in sarcopenic obesity, a high-risk geriatric condition associated with metabolic perturbations and several co-morbidities. Despite the rising numbers of older adults diagnosed with sarcopenic obesity, few studies have characterized this condition on the muscle cell and systemic level. This study sought to comprehensively assess the influence of sarcopenic obesity on muscle and blood-related parameters and compare it to non-sarocopenic obese and non-sarcopenic lean older adults.

Interventions

DIETARY_SUPPLEMENTEssential amino acids (EAA)

intake of 240 mg EAA per kg lean body mass after a resistance exercise session

Sponsors

The Swedish School of Sport and Health Sciences
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years

Inclusion criteria

* Body fat % in accordance with previously defined criteria * Free of smoking (since 10 years) * Able to walk without assistance * Able to perform bilateral leg extension exercise

Exclusion criteria

* History of or present disease of myocardial, vascular, endocrine, hepatic, renal, pulmonary or neuromuscular origin * Uncontrolled hypo/hypertension * Use of anticoagulants (Warfarin, Trombyl) * Use of metformin or other anti-diabetic medications * Poor appetite and unexplained weight loss (4,5 kg) over the past 6 months * Active malignancy * Present infection * Dementia or delirium * Other conditions that may interfere with the study protocol in the opinion of the PI

Design outcomes

Primary

MeasureTime frameDescription
Fiber type-specific cell signalling1 hour after ingestion of essential amino acids and resistance exerciseThis measure will be investigated during an experimental trial in which the participants are subjected to an acute bout of resistance exercise followed by the ingestion of essential amino acids (240 mg/kg lean mass). During this 3 hour time period, the participants will donate two muscle biopsies, one before exercise and the second one 1 hour after exercise. Cell signalling networks related to muscle mass regulation will be examined in these biopsy samples. The signal will be measured using Western blotting and the signal obtained is expressed in relation to baseline (adjusted volume intensity).

Secondary

MeasureTime frameDescription
Skeletal muscle fiber characteristics1 hour prior to ingestion of essential amino acids and resistance exerciseFiber type-specific area measured using immunofluorescence microscope in muscle biopsies collected at baseline (prior to ingestion of essential amino acids and resistance exercise). Unit of measurement is square micrometers (µm\^2).
Whole body muscle volume1 hourIndices of muscle volume and fat infiltration obtained with magnetic resonance imaging (MRI). Unit of measurement is cubic centrimeters (cm\^3).
Whole body glucose tolerance2 hoursOral glucose tolerance test in which the participants will ingest a standardized glucose drink and blood glucose levels will be monitored throughout a period of 2 hours. Unit of measurement is mmol/L glucose.
Accelerometer-assessed physical activity levels1 weekHip-worn accelerometer data (Actigraph GT3X) collected over 7 consecutive days. Unit of measurement is steps per day.
Isometric and isokinetic leg muscle strength1 hourMuscle performance will be evaluated at a single timepoint during the study using IsoMed2000 dynamometer. Participants will perform a maximal isometric contraction at 60 degrees of knee flexion. Unit of measurement is Newton meter (N-m).

Countries

Sweden

Contacts

Primary ContactWilliam Apró, PhD
william.apro@gih.se08-120 538 67

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026